Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi (SNY) Q4 2024 Earnings Call Transcript
02:41pm, Thursday, 30'th Jan 2025
Sanofi (NASDAQ:SNY ) Q4 2024 Results Conference Call January 30, 2025 9:00 AM ET Company Participants Thomas Larsen - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger -
Sanofi CEO Paul Hudson on RFK Jr.'s vaccine stance
10:30am, Thursday, 30'th Jan 2025
Sanofi CEO Paul Hudson discusses the company's quarterly earnings results and his thoughts on the confirmation hearing of RFK Jr.
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
09:15am, Thursday, 30'th Jan 2025
SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025.
Sanofi CEO Paul Hudson on Q4 results: We've set ourselves up very well for 2025
07:15am, Thursday, 30'th Jan 2025
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the confirmatio
Sanofi meets estimates for fourth-quarter profit, plans 5 billion euros in buybacks
01:33am, Thursday, 30'th Jan 2025
French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it se
'The next battleground': Sanofi exploring opportunities in second generation obesity drugs
01:00pm, Thursday, 23'rd Jan 2025
Paul Hudson, CEO of Sanofi, says his firm is exploring the second generation of obesity drugs, noting that solutions for sustained weight loss were "the next battleground."
SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma
08:50am, Thursday, 23'rd Jan 2025
The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line multiple myeloma in the EU.
Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
Press Release: Opella reaches study milestone for Cialis
01:00am, Tuesday, 21'st Jan 2025
Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi's Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on
Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript)
03:30pm, Tuesday, 14'th Jan 2025
Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ET Company Participants Paul Hudson - Chief Executive Officer Francois-Xavier Roger - Chief Financial Officer Houman Ashrafian
SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)
05:21am, Tuesday, 14'th Jan 2025
Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Sanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade)
11:45am, Friday, 10'th Jan 2025
Sanofi's Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 billion,
SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study
11:31am, Friday, 10'th Jan 2025
Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.
